TriCor Data Close At Hand; Will It Strike ACCORD With Physicians?
This article was originally published in The Pink Sheet Daily
Cardiovascular outcomes data comparing fenofibrate and simvastatin versus just the statin could have implications for Abbott's cholesterol franchise.
You may also be interested in...
Report from ACC: Experts advise reading the fine print of the study - which failed to show an overall outcome benefit - as sub-group analysis shows highest-risk patients might benefit.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.